Featured Article
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax® (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
Emergent is pleased with this development as it continues to grow its presence in the Pacific Rim,” said Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions. “With HSA approval of BioThrax, we look forward to initiating discussions with the government of Singapore, as well as other allied governments that recognize HSA registered products such as Brunei, to help protect their constituents against the threat of anthrax as a biological weapon.
US pharma's 277 drugs in R&D for skin diseases
More than 100 million Americans - or one-third of the population - suffer from at least one skin disease, and these range from acne to psoriasis and from melanoma to infections, says the report, from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Chemist solves riddle of killer anthrax, meningitis
Anthrax, septicemia and meningitis are some of the planet's most lethal infections. Now a chemist has uncovered the mechanism behind these deadly infections.
Global cases of diabetes climb to 347 million: study
Findings from a large-scale study published in The Lancet show that the number of people worldwide with diabetes has more than doubled since 1980. Majid Ezzati, from the UK's School of Public Health at Imperial College London, who led the study along with Goodarz Danaei from the Harvard School of Public Health 
New drug containing nitric oxide boosts snakebite survival time
A new study has shown that a class of compounds called nitric oxide donors delays the entry of toxins from potentially deadly snakebites.
KIMS to perform south India’s first robot assisted surgeries soon
In a major development, the Hyderabad-based multi super speciality hospital, Krishna Institute of Medical Sciences (KIMS), is all set to perform the first robotic assisted surgeries in south India.
Medical council wants Drugs Act repealed
The Tamil Nadu State Medical Council has asked the government to repeal the amendment to the rule under the Drugs and Cosmetics Act, which enabled practitioners of traditional medicine to prescribe allopathic drugs.
Mystery disease in Muzaffarpur continues to baffle doctors, toll rises to 44
The mystery disease in Bihar's Muzaffarpur district continues to claim more lives with the death toll now touching 44. Over the last 10 days, over 40 children have died due to this unknown virus.
REMI to launch new blood products in market with Barkey
REMI Group has made a formal announcement declaring its decision to make a foray in the segment of critical care equipment range in domestic market. The company has sealed an agreement with Barkey and would be acting as the local distributor and marketing partner for Barkey’s products.
Scientists reveal HIV weakness
Vaccines that target newly identified viral protein sequences could be more effective than previous efforts
India, UAE to step up investments
A day after foreign minister-level talks, India Tuesday said it has decided to step up two-way investments in the United Arab Emirates (UAE) and work towards enhancing the profile of their business relations, particularly in the infrastructure sector.
‘Double Dhamaal’ earns big in North America Bollywood’s new all-star comedy ‘Double Dhamaal’ has opened at number 18 on North American box office charts with a weekend gross of $301,831 despite only playing in 54 theatres across the US States and Canada.
Toyota's Rs 3.99L Etios Liva to take on Swift, i10 Japanese auto giant Toyota on Monday drove in Etios Liva compact at Rs 3.99 lakh (ex-showroom Delhi, entry-level model) to mark its presence in the high-volume small car segment in India
| 
No comments:
Post a Comment